Michael Nauck

58PUBLICATIONS
70CO-AUTHORS
PharmacogenomicsMedical parasitologySport and exercise nutritionCancer therapy (excl. chemotherapy and radiation therapy)Pharmaceutical delivery technologies
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (58)

|May 21, 2026
Causes and consequences of discontinuation of GLP1RAs or tirzepatide.

|Apr 13, 2026
Clinical Potential of GIP in Type 2 Diabetes and Obesity.

Michael Nauck, Fiona Gribble, Frank Reimann

|Apr 06, 2026
Estimating the True MACE Benefits From Tirzepatide in SURPASS-CVOT Using an Imputed Placebo Analysis of REWIND.

Naveed Sattar, Hertzel C Gerstein, David D'Alessio

|Mar 19, 2026
Challenging the Consensus Statement: Is It Time to Recognise Pharmacological Remission of Type 2 Diabetes?

Cristina Bianchi, Stefano Del Prato, Amy E Rothberg

|Feb 27, 2026
Dose-Escalation Regimens for Incretin Mimetics in Type 2 Diabetes Are Associated With Tolerance for Nausea and Vomiting.

Michael A Nauck, Viktoria Punov, Yu Mi Kang

|Dec 17, 2025
Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes.

Stephen J Nicholls, Imre Pavo, Deepak L Bhatt

Pageof 10

Frequent Collaborators

8 joint publications

Juris J Meier

6 joint publications

Daniel R Quast

5 joint publications

Carel W le Roux

5 joint publications

Karen L Jones